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Summary.-The incidence of tumours ectopically producing the human chorionic
gonadotrophins was studied in patients with breast cancer. Specific radioimmuno-
assay of subunits of HCG was utilized. Nine out of 65 patients with carcinoma of
breast showed the presence of circulating HCG. Patients with other pathological
conditions of breast tissue did not show any evidence of circulating HCG.
OBSERVATIONS indicating ectopic pro-
duction of the gonadotrophins have been
made in the past. Fusco and Rosen
(1966) measured increased levels of gona-
dotrophins in the urine of 4 patients with
advanced bronchogenic carcinoma. They
also showed the presence of gonadotro-
phins in the tumour tissue. Since then a
number of observations on gonadotrophin
production in men having bronchogenic
carcinoma have been reported (Faiman
et al., 1967; Becker et al., 1968; Rosen etal.,
1968). Similar studies on ectopic produc-
tion of gonadotrophins by hepatoma
(Reeves, Tesluk and Harrison, 1959),
hepatoblastoma (Root, Bogiovanni and
Eberlein, 1968), adrenocortical carcinoma
(Rose et al., 1968), and carcinoma of the
breast (McArthur, 1963) have been re-
ported, but literature on gonadotrophins
in carcinoma of the breast is limited.
Until 1972, no method was available for
distinguishing gonadotrophins secreted by
the tumours from that secreted by the
pituitary gland. The recognition ofectopic
production of gonadotrophin depended on
finding a neoplasm associated with a
quantity of gonadotrophin in urine or
plasma in excess of that expected from
pituitary secretion alone. Recentdevelop-
ment of a radioimmunoassay method for
the estimation of the ,3 subunit of human
chorionic gonadotrophin (HCG) has pro-
vided an ideal tool which selectively
measures HCG in samples of blood or
urine. Circulating levels of leuteinizing
hormone (LH) originating from the pitui-
tary does not interfere with the estimation
of HCG. The assay system has made use
of the recent knowledge provided by Bahl
(1969) and Bell, Canfield and Schiarra
(1969) on the characterization and isola-
tion of the /l subunit of HCG. It is now
known that the ,3 subunit of HCG has a
structure distinct from that of HLH.
Thus, antisera generated to the /3 subunit
ofHCG clearlv discriminate within certain
limits between HLH and HCG, whereas
most of those produced following immuni-
zation with intact HCG do not.
Utilizing this assay system, we have
tried to scan serum samples from a large
number of patients with cancer of the
breast, to estimate the incidence of HCG
secreting breast tumours.
MATERIALS AND METHODS
Antigen and antisera. Highly purified f
subunit of HCG and antisera to f HCG were
generously provided by NIAMD, Bethesda,
U.S.A. The Second International Standard
for HCG, wNhich served as a reference prepara-
tion for these assays, -was obtained from the
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Clinical material.-Serum samples separ-
ated from whole blood were stored at - 20°C
until use. Serum samples from 65 patients
with established carcinoma of breast, 10
patients with cystic mastitis, 5 with gynaeco-
mastia and 7 with fibroadenoma were col-
lected from the clinic of the Tata Memorial
Hospital. In all the above cases, pregnancy
was ruled out. Histopathological diagnosis
was carried out in the Pathology Department
oftheHospital. Bloodsamplesfrompatients
with choriocarcinoma, normal men and
normal non-pregnant and pregnant women
were also collected for comparative studies.
Iodination.-Carrier-free 125Iwasobtained
from the Radiochemical Centre, Amersham,
England. The method of Greenwood, Hunt-
er and Glover (1963) as modified by Midgley
(1966) was used to iodinate the : subunit of
HCG. To 2-5 jig of subunit dissolved in
phosphate buffer (pH 7.5), 1 mCi 125I and
30 jug (15 ,ul) of chloramine-T were added and
allowed to react for 90 s at room temp. The
reaction was stopped with the addition of
125 ,ug (50 jzl) of sodium metabisulphite.
Separation of iodinated hormone from free
iodine was achieved by passing the reaction
mixture through a column of Sephadex G-75,
which had been equilibrated with 5% egg
white in phosphate buffer with 0-14 mol/l
saline (PBS). The specific activities of
labelled hormones ranged from 100-150
,uCi/ig. To find out the extent of hormone
damage during iodination, 125I-labelled /
subunit ofHCG was precipitated by excess of
antibody to :3 subunit ofHCG. It was found
that 90-95% ofthe labelled hormone could be
precipitated by the antibody. These results
indicated that damage due to iodination was
very little.
Assay.-All assays were carried out by the
double antibody technique as described by
Midgley (1966). After incubation of the
antigen with the antiserum and labelled
hormone for 48 h at 4°C in a final volume of
0-8 ml, a second antibody (sheep anti-rabbit
gamma globulin) was added. Incubation
was continued for another 48 h at 4°C. At
the end ofthe incubation period, the contents
of each tube were diluted to 3 ml with PBS
containing 0-1% gelatin. Finally, bound
and free hormones were separated by centri-
fugation. The tubes were drained and the
amount of bound radioactive tracer was
determined by gamma ray spectrometry.
All serum samples were run in duplicate. The
inter-assay coefficient of variation was 7-8%
and that of intra-assay was less than 5%.
RESULTS
The Figure shows the standard curve
of international reference standard of
HCG with the antiserum against , subunit
of HCG and radio-iodinated ,8 HCG. The
sensitivity of the assay is up to 2 mIU/per
tube, 5 mIU of HCG/ml.
Table I shows that , HCG was de-
tected in 9 out of 65 women having
carcinoma of breast, when 200 1,u1
serum samples were used for the assay.
As can be seen from the Table, serum
samples from patients with cystic mastitis,
gynaecomastia and fibroadenoma did not
show positive tests for HCG when tested
in 200 ,al of serum. Serum samples from
normal men and non-pregnant women, as
well as post-menopausal women, did not
show,l HCG even when tested at 400 ,ul of
serum. As could be expected in pregnant
women and women with choriocarcinoma,
positive reactions for the presence of ,
HCG were obtained with serum samples as
little as 1 ,ul or less.
Table II shows the amount of , HCG
measured in serum samples of patients
with breast cancer. It may be noted that
in the majority ofpatients the amounts of
HCG in serum varied from 10 mIU to
15 mIU per ml of serum. In a few
positive cases, the blood samples were
collected after a few months, where
possible, so as to confirm the presence of
circulating / HCG. It may be noted
(Table II) that the serum levels of HCG
remain constant in case ofpatients Nos. 2,
3 and 5 at the time of repeat testing, while
in patient No. 4 the levels are found to
increase from 8 mIU to 150 mIU after a
4 months' period. Further studies are
needed on the levels of the hormone and
on correlation of the course of the disease
with the levels of HCG.
DISCUSSION
Although studies indicating ectopic
production of gonadotrophin by breast
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FIG. 1. Dose r,espoinse curve foI the human chorionic gona(lotrophin (HCG II, IR).
TABLE I. Human Chorionic Gonadotrophin in Serum of Women with Various
Pathological and Physiological Conditions and of Control Men and Women
Diagnosis
Carcinoma of breast
Cystic mastitis
Fibroa(lenoma
Gynaecomastia
Choriocarcinoma
Pregnancy 1st trimester
Pregnancy 2nd trimester
Pregnancy :3rd trimester
Normal wvomen
(non-pregnant)
Post-menopausal Avomeni
Normal men
No. of
cases
stu(lied
65
10
7
5
8
10
15
1 0
6
4
6
tumours have been reported in the past,
observations on large numbers of breast
cancer patients, with a view to studying
the incidence of HCG secreting breast
tumours, are very few. Our data indicate
that the incidence ofHCG secreting breast
tumours is around 13% (9 of 65 cases). It
No. of
positive
cases
9
none
none
none
8
10
15
10
none
none
i)one
fB HCG/ml serum
10-15 mIU
nil
nil
nil
24-34-5 IU
8-6±1-8 IU
2-4±0-5 IU
4-8±1*2 IU
nil
nil
nil
should be noted that the levels of hor-
mones are not very high, except in one
case. The incidence noted by us is
slightly higher than that observed bv
Braunstein et al. (1973) which is around
90o (3 of 33). These authors, utilizing
radioimmunoassay of /1 subunit of HCG,
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TABLE II. Levels of/1 HOG in Serqum SamPles of Individual Breast Cancer Patients
Serial nio. Age
1 42
2 44
2nd sample
3
3
2ncd sample
4
4
2nd sample
3rd1 sample
5
6
6
2nd sample
7
8
38
50
M\enstrual statuis
Premenopausal
Premeneopausal
40 Premenop)ausal
42 Premenopausal
\lMenopausal
Post-menopausal
Histology
Infiltrating deict carcinioma
Grade 2
Infiltrating duct carciinoma
Gradte 3
Infiltiatiing (luct carciinoma
Grade 2
Infiltrating (luct carcinoma
Grade 3
Infiltrating dltict carcinoma
Grade 3
Inifiltrating d(bet carcinoma
Grade 2
64 Post-meinopauLsal Car-cinoma non-specified
60 Post-meinopausal Caicinoma non-specified
9 50 Post-menopauisal infiltrating (uct
carcinoma
fl-HCG
mIU/ml
serum
10
15
15
Other iniformation
AMetastatic carcinoma of
breast
.Metastatic carcinoma of
breast. Ovaries normal
Secondl sample of bloo(d
collected after 5 months
10 Mletastatic carcinoma of
breast
15 Second sample of bloodl
collected after 4 months
8 Metastatic carcinoma of
breast. Ovaries normal
80 Secon(d sample collected
after 2 months
150 Third sample of bloodl
collectedl after 4 months
15 'Metastatic carcinoma of
breast
10 Metastatic carcinoma of
breast
10 Secon(d sample collected
after one month
12 Metastatic carcinoma of
breast
10 AMetastatic carcinoma of
breast
10 Metastatic carcinoma of
breast. Ovaries normal
also reported a high incidence of measure-
able levels of this hormone in patients
with carcinoma of stomach, liver and
pancreas, and multiple myeloma and
melanoma. Our finding that a significant
number of breast cancer patients have
HCG secreting neoplasms indicates the
potential use of this test as a diagnostic
tool as well as a marker to study the
course of the disease during the treatment
of the patients. However, the presence
of material reacting in the immunoassay
to the 1i subunit of HCG does not neces-
sarily imply that the humans are secreting
whole HCG. Of course, it remains to be
checked whether at a very early stage
tumours do secrete the hormone or not,
and whether this property of the tumour
is acquired at a later stage of its
development.
Finally, the explanation for the syn-
thesis of hormones by various non-
endocrine tumours is still an unresolved
problem. Currently three theories are
suggested. The first theory (Bower and
Gordan, 1965) is that only a part of the
protein molecule of the hormone is
synthesized, due to chaotic synthesis
characteristic of the neoplastic cells,
whereby the hormone thus produced may
have biological properties similar to the
natural hormone, yet immunologically it
may be a distinct entity. TSH and insulin
secreted by tumours provide good ex-
amples of this theory, yet there are other
hormones secreted by tumours which are
identical to the natural hormones both
biologically and immunologically. Another
theory (Unger, Lochner and Eisentraut,
1964) which does not have good supporting
evidence, suggests that the tumour may
have the capacity to store the hormone
from the circulating pool of hormone.
This stored hormone is released when
malignant cells of an enlarging tumour are
broken down. The third view (Hobbs and
Miller, 1966) suggests that the malignant
cells revert to the synthesis of various
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peptides by inactivation of histone re-
pressor or deletion of a regulator gene that
is normally thought to produce a repressor
which combines with the operator slowing
the manufacture of a messenger RNA
molecule. According to this theory, the
hormone produced by the tumour may be
very similar to the natural hormone.
Secretion ofACTH, TSH andvassopressin,
which possess biological and immuno-
logical characteristics similar to natural
hormone, is good supporting evidence for
the above theory. More work needs to be
carried out for the evolution of a proper
theory.
We are grateful to Dr D. J. Jussawalla,
Director, Tata Memorial Centre, and
Dr (Mrs) Shanta S. Rao, Deputy Director,
Institute for Research in Reproduction
for giving us the facilities to carry out this
investigation.
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